Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy

Purpose To investigate the incidence and risk factors for oral mucositis (OM) in patients with childhood cancer undergoing chemotherapy. Methods Eight hundred and twenty-nine cycles of chemotherapy were evaluated in 112 patients with childhood cancer undergoing chemotherapy. Chemotherapy protocol, h...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2021-11, Vol.29 (11), p.6243-6251
Main Authors: Curra, Marina, Gabriel, Amanda F., Ferreira, Maria Beatriz C., Martins, Marco Antonio T., Brunetto, André T., Gregianin, Lauro J., Martins, Manoela Domingues
Format: Article
Language:English
Subjects:
Bilirubin
Cancer
Cancer patients
Chemotherapy
Children
Comparative analysis
Cyclophosphamide
Health aspects
Hematology
Hemoglobin
Leukemia
Lymphomas
Medicine
Medicine & Public Health
Mucositis
Nursing
Nursing Research
Oncology
Oncology, Experimental
Original Article
Pain Medicine
Pediatrics
Rehabilitation Medicine
Risk factors
Sarcoma
Stomatitis
Toiletries industry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To investigate the incidence and risk factors for oral mucositis (OM) in patients with childhood cancer undergoing chemotherapy. Methods Eight hundred and twenty-nine cycles of chemotherapy were evaluated in 112 patients with childhood cancer undergoing chemotherapy. Chemotherapy protocol, hematological, hepatic, and renal function parameters were collected and compared to presence and severity of OM, as graded by the World Health Organization (WHO) scale. Patients received counseling on oral hygiene and those who presented with OM (grade ≥1) received photobiomodulation therapy (PBMT). Results Age ranged from 0 to 17 years (mean/SD, 8.58 ± 5.05) and fifty-one patients (45.54%) were females. The most common baseline diseases were leukemia (51%) followed by sarcomas (23%) and lymphomas (18%). Eight hundred and twenty-nine cycles of chemotherapy were evaluated, and OM was diagnosed in 527 cycles (63.57%). Higher incidence and severity of OM was observed in protocols using high-dose methotrexate (MTX-HD), MTX-HD cyclophosphamide/doxorubicin combination, and MTX-HD combined with cyclophosphamide ( p
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-021-06199-5